{
  "query": "free model relapse time",
  "studies": {
    "protocolSection": [
      {
        "identificationModule": {
          "nctId": "NCT04875325",
          "briefTitle": "Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Resectable Pancreatic Ductal Adenocarcinoma", "Recurrent Pancreatic Ductal Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 306,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06674382",
          "briefTitle": "Haplo-HSCT for Myelofibrosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Myelofibrosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04128501",
          "briefTitle": "Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-05-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Bilineal Leukemia", "Acute Biphenotypic Leukemia", "Acute Myeloid Leukemia", "Mixed Phenotype Acute Leukemia", "T Acute Lymphoblastic Leukemia", "Therapy-Related Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 125,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04684563",
          "briefTitle": "huCART19-IL18 in CD19+ Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-05-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2036-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Chronic Lymphocytic Leukemia", "Non-hodgkin Lymphoma", "Acute Lymphoblastic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 72,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00072384",
          "briefTitle": "Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-04-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Intraocular Retinoblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "17 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01797965",
          "briefTitle": "Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-02-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-09-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Relapsing-Remitting Multiple Sclerosis", "Multiple Sclerosis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1501,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01678430",
          "briefTitle": "A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-12"
          },
          "completionDateStruct": {
            "date": "2017-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Chronic Lymphocytic Leukaemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 670,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03263767",
          "briefTitle": "Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-01-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-06-21",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Graft Versus Host Disease"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 47,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06692556",
          "briefTitle": "Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cutaneous Squamous Cell Carcinoma (CSCC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 266,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05564650",
          "briefTitle": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-01-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-05-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Myelodysplastic Syndrome", "Recurrent Myelodysplastic Syndrome", "Refractory Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 6,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07213427",
          "briefTitle": "Outcomes of Image-guided High-dose-rate Uterovaginal Brachytherapy With Single Implantation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "LOCALLY ADVANCED CERVICAL CANCERS"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 363,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02339740",
          "briefTitle": "Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-07-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-09-22",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 158,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Months",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03600155",
          "briefTitle": "Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-10-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Allogeneic Hematopoietic Stem Cell Transplantation Recipient", "Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07102056",
          "briefTitle": "18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Neuroendocrine Tumors"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 152,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01943851",
          "briefTitle": "A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-05-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-04-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 111,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04417062",
          "briefTitle": "Olaparib With Ceralasertib in Recurrent Osteosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-11-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Osteosarcoma", "Osteosarcoma Recurrent"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 63,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years",
          "maximumAge": "40 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05415579",
          "briefTitle": "Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-20",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2030-05-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Demyelinating Diseases of the Central Nervous System (DDC)"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 2000,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01959698",
          "briefTitle": "Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-04-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["CD20 Positive", "Recurrent Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Stage I Diffuse Large B-Cell Lymphoma", "Stage II Diffuse Large B-Cell Lymphoma", "Stage III Diffuse Large B-Cell Lymphoma", "Stage IV Diffuse Large B-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04289220",
          "briefTitle": "Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-03-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-09-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["B Cell Lymphoma", "B-cell Acute Lymphoblastic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00002706",
          "briefTitle": "Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "1996-04"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": ["Endometrial Adenocarcinoma", "Stage I Uterine Corpus Cancer", "Stage I Uterine Sarcoma", "Stage II Uterine Corpus Cancer", "Stage II Uterine Sarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2616,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01476839",
          "briefTitle": "Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-11-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-05-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Adult Hodgkin Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02732275",
          "briefTitle": "DS-3201b in Participants With Lymphomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-03-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphoma, Malignant", "Non-hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07183878",
          "briefTitle": "Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-08-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-08-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "High-Risk Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "High-Risk Myelodysplastic Syndromes"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 138,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01393405",
          "briefTitle": "Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Ulcerative Colitis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 179,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05929768",
          "briefTitle": "Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2033-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Early Stage Triple-Negative Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2400,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06871410",
          "briefTitle": "Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-04-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 26,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01025154",
          "briefTitle": "Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-01"
          },
          "completionDateStruct": {
            "date": "2013-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 63,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01620970",
          "briefTitle": "PF-03446962 in Relapsed or Refractory Urothelial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-03-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2013-06-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Transitional Cell Carcinoma of Bladder"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05098405",
          "briefTitle": "First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-01-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Malignant Solid Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 46,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06605131",
          "briefTitle": "GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-17",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-02-25",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Nasopharyngeal Cancinoma (NPC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 72,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "6 Years",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05303792",
          "briefTitle": "Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-06-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["B Acute Lymphoblastic Leukemia", "B Lymphoblastic Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 68,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "50 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06222801",
          "briefTitle": "The 1st Tumor CytokinoTherapy Database (TCTD-1)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-09-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2032-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Oncology"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 5000,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "95 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03164057",
          "briefTitle": "A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-06-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Myelodysplastic Syndromes"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 206,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "29 Days",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03795207",
          "briefTitle": "Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-03-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-27",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Node; Prostate", "Bone Metastases", "Prostate Cancer Patients"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 96,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06852807",
          "briefTitle": "18F-mFBG PET Imaging in the Evaluation of Neuroblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-02-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Neuroblastoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02904577",
          "briefTitle": "Indolent Non Follicular Lymphomas Prognostic Project"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Indolent B-Cell Lymphomas"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 370,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05634915",
          "briefTitle": "Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-12-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-05-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Hematopoietic Stem Cell Transplantation", "Acute Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "16 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02212561",
          "briefTitle": "Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia (AML)", "Acute Lymphoblastic Leukemia (ALL)", "Myelodysplastic Syndrome (MDS)", "Mixed Phenotype Acute Leukemia (MPAL)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "24 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04053231",
          "briefTitle": "Hepatocarcinoma Recurrence on the Liver Study - Part2"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-09",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2034-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Liver Cancer", "Surgery", "Recurrence Tumor", "Cirrhosis"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 3000,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06933966",
          "briefTitle": "Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-09-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2032-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma", "Non Metastatic Disease"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02657928",
          "briefTitle": "Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-07-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-10-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Estrogen Receptor Positive", "Postmenopausal", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03791073",
          "briefTitle": "New Biomarkers in Pancreatic Cancer Using EXPEL Concept"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-11-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Oncology"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07228273",
          "briefTitle": "Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-24",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-08-24",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 102,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06735690",
          "briefTitle": "Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-03-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Lymphoblastic Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02181179",
          "briefTitle": "Examining Yoga's Effects on Smoking"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-07"
          },
          "completionDateStruct": {
            "date": "2017-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Yoga", "Waitlist"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07082270",
          "briefTitle": "Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-02-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-02-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Multiple Myeloma", "Refractory Multiple Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06556550",
          "briefTitle": "Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-05-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Oligometastatic Disease"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03701724",
          "briefTitle": "Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-11-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Treatment-resistant Depression"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 119,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02169505",
          "briefTitle": "Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-05-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-08-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04818359",
          "briefTitle": "Movement and Health Beyond Care (MoviS)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-01-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer Survivors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 172,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "30 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03701308",
          "briefTitle": "Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-03-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 264,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01329289",
          "briefTitle": "SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-12"
          },
          "completionDateStruct": {
            "date": "2012-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Multiple Myeloma in Relapse", "Multiple Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04205409",
          "briefTitle": "Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-06-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-08-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Grade 3a Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00803049",
          "briefTitle": "Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-10"
          },
          "completionDateStruct": {
            "date": "2015-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 742,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01920932",
          "briefTitle": "Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-08-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage II Childhood Hodgkin Lymphoma", "Stage III Childhood Hodgkin Lymphoma", "Stage IV Childhood Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 77,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06107582",
          "briefTitle": "Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-11-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2036-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Primary Immune Thrombocytopenia"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 500,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "sex": "ALL",
          "minimumAge": "6 Years",
          "maximumAge": "17 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04859946",
          "briefTitle": "Itacitinib for the Prevention of Graft Versus Host Disease"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-01-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-04-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hematologic and Lymphocytic Disorder"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 31,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07187726",
          "briefTitle": "Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted Risk"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-10-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-01-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Unilateral Breast Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 724,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01180049",
          "briefTitle": "Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Hodgkin's Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 101,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07045168",
          "briefTitle": "Risk-adapted Therapeutic Strategy in +1q NDMM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-09-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-07-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03589274",
          "briefTitle": "Testing CBT Models and Change Mechanisms for Alcohol Dependent Women"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-06-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2014-04-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Alcohol Use Disorder"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 155,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06408441",
          "briefTitle": "The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-12-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2033-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Epithelioid Hemangioendothelioma", "Sarcoma,Soft Tissue"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07152041",
          "briefTitle": "Newly-diagnosed Pediatric Ph-positive B-ALL Protocol"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-03-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)", "Childhood Leukemia, Acute Lymphoblastic"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "1 Month",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03874052",
          "briefTitle": "Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-08-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Recurrent Secondary Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Secondary Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 51,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00145626",
          "briefTitle": "HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-05"
          },
          "completionDateStruct": {
            "date": "2016-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Myelodysplasia", "Chronic Myeloid Leukemia", "Histiocytosis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "24 Months"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01536561",
          "briefTitle": "Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "1990-04-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2009-10-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, Non-Hodgkin"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 59,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06522529",
          "briefTitle": "Sumamos Excelencia Project: Implementation of Best Practices in Clinical Practice (Thrid Edition)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-09-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-01-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Pain", "Obesity, Childhood", "Breast Feeding", "Incontinence, Urinary", "Smoking Cessation", "Pressure Injury", "Fall"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 400,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02250937",
          "briefTitle": "Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-10-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 116,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06057298",
          "briefTitle": "Patient-tailored Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases (OrganoHIPEC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-06-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-06-14",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Peritoneal Metastases From Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07213882",
          "briefTitle": "A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-08-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Cutaneous T Cell Lymphoma (CTCL)", "Mycosis Fungoides", "Sezary Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00875433",
          "briefTitle": "Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-03"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": "Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05711628",
          "briefTitle": "A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-08-10",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Classic Hodgkin Lymphoma", "Refractory Classic Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "5 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01368263",
          "briefTitle": "Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-09"
          },
          "completionDateStruct": {
            "date": "2013-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Estrogen Receptor-positive Breast Cancer", "HER2-negative Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01562028",
          "briefTitle": "BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-06"
          },
          "completionDateStruct": {
            "date": "2018-10-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 109,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03571828",
          "briefTitle": "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-10-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-01-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Diffuse Large B-cell Lymphoma(DLBCL)", "Mantle Cell Lymphoma (MCL)", "Follicular Lymphoma (FL)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04370574",
          "briefTitle": "Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Neoplasms"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03531918",
          "briefTitle": "Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-11-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 66,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02071901",
          "briefTitle": "Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-08-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-09-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Secondary Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 31,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04474964",
          "briefTitle": "Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-08-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Medulloblastoma, WNT-activated"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "3 Years",
          "maximumAge": "16 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00436826",
          "briefTitle": "A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-11-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2012-03-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 172,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04205240",
          "briefTitle": "Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-11-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Plasma Cell Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04788615",
          "briefTitle": "Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-11-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 185,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02034123",
          "briefTitle": "Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-02-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-04-18",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Small Cell"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05933226",
          "briefTitle": "Project Khanya: Peer-Delivered Intervention to Improve HIV Medication Adherence and Substance Use in South Africa"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-06-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Human Immunodeficiency Virus", "Alcohol-Related Disorders", "Drug Use", "Substance Use"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 160,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00796562",
          "briefTitle": "Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["MDS", "Leukemias", "Lymphomas"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 107,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "6 Months",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05596422",
          "briefTitle": "A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-05-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-12-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Inflammatory Bowel Disease (IBD)", "Ulcerative Colitis", "Crohn's Disease"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 423,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06150417",
          "briefTitle": "MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-04-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Prostate Cancer", "Malignant Neoplasm of Prostate", "Secondary Malignant Neoplasm of Prostate"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04269902",
          "briefTitle": "Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-10-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 247,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05290961",
          "briefTitle": "The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-03-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Ovarian Neoplasms"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02190968",
          "briefTitle": "Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Major Depressive Disorder, Recurrent, in Remission", "Depressive Symptoms"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 460,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02827149",
          "briefTitle": "High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-09-21",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hematologic Diseases"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 1838,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05656248",
          "briefTitle": "Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-01-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Myeloid Neoplasm"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "1 Year",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02419378",
          "briefTitle": "Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Sclerosis, Relapsing-Remitting"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06855810",
          "briefTitle": "Newly-diagnosed Pediatric T-cell ALL Protocol"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-03-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2031-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Lymphoblastic Leukemia", "Childhood Leukemia, Acute Lymphoblastic", "T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 610,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "1 Month",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02573363",
          "briefTitle": "Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-10-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-05-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03827343",
          "briefTitle": "Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-01-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Macrophage Activation Syndrome", "Primary Hemophagocytic Lymphohistiocytosis"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 500,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "1 Month",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02298855",
          "briefTitle": "Individualised Versus Conventional Medical Follow-up for Women After Primary Treatment for Ovarian Cancer."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-01"
          },
          "completionDateStruct": {
            "date": "2010-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 113,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07200089",
          "briefTitle": "Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-31",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-07-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Multiple Myeloma", "Multiple Myeloma in Relapse", "Multiple Myeloma, Refractory"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01729806",
          "briefTitle": "Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-11-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-03-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["CD20 Positive", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 32,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02405078",
          "briefTitle": "Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-10-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-10-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ],
    "protocolSection.1": [
      {
        "identificationModule": {
          "nctId": "NCT03441958",
          "briefTitle": "ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-10-17",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04786002",
          "briefTitle": "Target Busulfan Exposure in Children With HSCT in China"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-11-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hematopoietic Stem Cell Transplantation"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 500,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "0 Years",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00303966",
          "briefTitle": "Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-11"
          },
          "completionDateStruct": {
            "date": "2011-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Refractory Chronic Lymphocytic Leukemia", "Stage I Chronic Lymphocytic Leukemia", "Stage II Chronic Lymphocytic Leukemia", "Stage III Chronic Lymphocytic Leukemia", "Stage IV Chronic Lymphocytic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06649812",
          "briefTitle": "Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-10-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02857712",
          "briefTitle": "Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-12"
          },
          "completionDateStruct": {
            "date": "2019-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Salivary Gland Cancers"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 26,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02166463",
          "briefTitle": "Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-03-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ann Arbor Stage IIB Hodgkin Lymphoma", "Ann Arbor Stage IIIB Hodgkin Lymphoma", "Ann Arbor Stage IVA Hodgkin Lymphoma", "Ann Arbor Stage IVB Hodgkin Lymphoma", "Childhood Hodgkin Lymphoma", "Classic Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 600,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years",
          "maximumAge": "22 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03572634",
          "briefTitle": "Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-06-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-01-21",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Chronic Lymphocytic Leukemia", "CLL", "SLL", "Small Lymphocytic Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04046575",
          "briefTitle": "Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-11-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-11-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Esophagus Cancer", "Esophageal Cancer", "Cancer of the Esophagus"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02603419",
          "briefTitle": "Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-03-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-04-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hodgkins Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00879658",
          "briefTitle": "Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-03-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-05-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsing-remitting Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 297,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03604978",
          "briefTitle": "Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-06-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Grade 2 Meningioma", "Grade 3 Meningioma", "Recurrent Meningioma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02328755",
          "briefTitle": "Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-01"
          },
          "completionDateStruct": {
            "date": "2019-03-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00751881",
          "briefTitle": "An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-08"
          },
          "completionDateStruct": {
            "date": "2015-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1169,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05563844",
          "briefTitle": "Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Diffuse Large B Cell LymphomaDLBCL"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 74,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06268379",
          "briefTitle": "BMA and Dynamic Nomogram for Survival Prediction in Patients With CRC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-02-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-12-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Colon Cancer", "Model Disease"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 2475,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "sex": "ALL",
          "minimumAge": "22 Years",
          "maximumAge": "101 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03245450",
          "briefTitle": "Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-05-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Refractory or Recurrent Solid Tumors", "Rhabdomyosarcoma", "Non-Rhabdomyosarcoma Soft Tissue Sarcoma", "Ewing Sarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "6 Months",
          "maximumAge": "25 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03749018",
          "briefTitle": "Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-01-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Aggressive Non-Hodgkin Lymphoma", "Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Indolent Non-Hodgkin Lymphoma", "Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma", "Transformed Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04157348",
          "briefTitle": "Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-10-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-03-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Eosinophilic Granulomatous Vasculitis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 140,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "130 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06274268",
          "briefTitle": "Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-05-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Sarcopenia", "Oncology", "Physical Inactivity", "Toxicity Due to Chemotherapy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 700,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04939597",
          "briefTitle": "A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-05-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Central Nervous System Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 192,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "4 Years",
          "maximumAge": "17 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05920096",
          "briefTitle": "Feasibility of a Diabetes Specialist Nurse-led Smoking Cessation Intervention"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-08-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-10-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Diabetes Mellitus", "Tobacco Use Cessation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 91,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02333058",
          "briefTitle": "Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-11-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-09-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Lymphoblastic Leukaemias (ALL)", "Acute Myeloid Leukaemias (AML)", "Myelodysplastic Syndromes (MDS)", "Juvenile Myelomonocytic Leukaemias (JMML)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 70,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "28 Days",
          "maximumAge": "17 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00136084",
          "briefTitle": "Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2002-08"
          },
          "completionDateStruct": {
            "date": "2012-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Leukemia, Myelocytic, Acute"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 238,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05229198",
          "briefTitle": "ALBATROSS Study: International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated at Vascular Habitats of High-grade Gliomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-06-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-06-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Astrocytoma, Grade IV"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 300,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06134375",
          "briefTitle": "A Study of Tetrathiomolybdate (TM) Plus Capecitabine"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2034-11-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Triple Negative Breast Cancer", "Residual Disease"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 204,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02007200",
          "briefTitle": "Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-07"
          },
          "completionDateStruct": {
            "date": "2015-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Verrucous Carcinoma", "Recurrent Lip and Oral Cavity Squamous Cell Carcinoma", "Recurrent Oral Cavity Verrucous Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage I Hypopharyngeal Squamous Cell Carcinoma", "Stage I Laryngeal Squamous Cell Carcinoma", "Stage I Laryngeal Verrucous Carcinoma", "Stage I Lip and Oral Cavity Squamous Cell Carcinoma", "Stage I Oral Cavity Verrucous Carcinoma", "Stage I Oropharyngeal Squamous Cell Carcinoma", "Stage II Hypopharyngeal Squamous Cell Carcinoma", "Stage II Laryngeal Squamous Cell Carcinoma", "Stage II Laryngeal Verrucous Carcinoma", "Stage II Lip and Oral Cavity Squamous Cell Carcinoma", "Stage II Oral Cavity Verrucous Carcinoma", "Stage II Oropharyngeal Squamous Cell Carcinoma", "Stage III Hypopharyngeal Squamous Cell Carcinoma", "Stage III Laryngeal Squamous Cell Carcinoma", "Stage III Laryngeal Verrucous Carcinoma", "Stage III Lip and Oral Cavity Squamous Cell Carcinoma", "Stage III Oral Cavity Verrucous Carcinoma", "Stage III Oropharyngeal Squamous Cell Carcinoma", "Stage IV Hypopharyngeal Squamous Cell Carcinoma", "Stage IVA Laryngeal Squamous Cell Carcinoma", "Stage IVA Laryngeal Verrucous Carcinoma", "Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVA Oral Cavity Verrucous Carcinoma", "Stage IVA Oropharyngeal Squamous Cell Carcinoma", "Tongue Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 55,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years",
          "maximumAge": "79 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06351644",
          "briefTitle": "ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-10-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-04-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed and/or Refractory Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06505837",
          "briefTitle": "JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung CancerNSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 395,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03067181",
          "briefTitle": "Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-05-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Childhood Extracranial Germ Cell Tumor", "Extragonadal Embryonal Carcinoma", "Germ Cell Tumor", "Malignant Germ Cell Tumor", "Malignant Ovarian Teratoma", "Stage I Ovarian Choriocarcinoma", "Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7", "Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7", "Stage I Testicular Choriocarcinoma AJCC v6 and v7", "Stage I Testicular Embryonal Carcinoma AJCC v6 and v7", "Stage I Testicular Seminoma AJCC v6 and v7", "Stage I Testicular Yolk Sac Tumor AJCC v6 and v7", "Stage II Ovarian Choriocarcinoma", "Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7", "Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7", "Stage II Testicular Choriocarcinoma AJCC v6 and v7", "Stage II Testicular Embryonal Carcinoma AJCC v6 and v7", "Stage II Testicular Yolk Sac Tumor AJCC v6 and v7", "Stage III Ovarian Choriocarcinoma", "Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7", "Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7", "Stage III Testicular Choriocarcinoma AJCC v6 and v7", "Stage III Testicular Embryonal Carcinoma AJCC v6 and v7", "Stage III Testicular Yolk Sac Tumor AJCC v6 and v7", "Stage IV Ovarian Choriocarcinoma", "Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7", "Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7", "Testicular Mixed Choriocarcinoma and Embryonal Carcinoma", "Testicular Mixed Choriocarcinoma and Teratoma", "Testicular Mixed Choriocarcinoma and Yolk Sac Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1780,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06606730",
          "briefTitle": "Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2039-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancers", "Triple Negative Breast Cancer (TNBC)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2454,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05103904",
          "briefTitle": "Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-04-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-11-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC V8", "Stage IIIA Hepatocellular Carcinoma AJCC V8", "Stage IIIB Hepatocellular Carcinoma AJCC V8", "Stage IV Hepatocellular Carcinoma AJCC V8", "Stage IVA Hepatocellular Carcinoma AJCC V8", "Stage IVB Hepatocellular Carcinoma AJCC V8", "Unresectable Hepatocellular Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05464082",
          "briefTitle": "Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-01-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer Recurrent"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06999980",
          "briefTitle": "Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2038-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Cutaneous Melanoma", "Mucosal Melanoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 494,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06172296",
          "briefTitle": "Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ganglioneuroblastoma, Nodular", "Neuroblastoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 478,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "30 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02563327",
          "briefTitle": "Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-08-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Tuberculosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 53,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05899465",
          "briefTitle": "Perioperative Treatment With Tranexamic Acid in Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-08-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1204,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06643221",
          "briefTitle": "Exercise as an Immune Adjuvant for Allogeneic Cell Therapies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-01-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Leukemia", "Hematopoetic Stem Cell Transplantation", "Donor Lymphocyte Infusion", "CAR T-Cell Therapy", "Lymphoma", "Cell Therapy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "21 Years",
          "maximumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04147533",
          "briefTitle": "Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-06-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Chronic Myeloid Leukemia, Chronic Phase", "Withdrawal;Drug"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03017833",
          "briefTitle": "Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-12-21",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Recurrent Malignant Solid Neoplasm", "Refractory Neoplasm"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 31,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06456463",
          "briefTitle": "A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-02-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 76,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06496178",
          "briefTitle": "A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Head and Neck Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 500,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04237168",
          "briefTitle": "Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2022-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, Large B-Cell, Diffuse"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04522362",
          "briefTitle": "Modeling Stress-precipitated Vaping Behavior"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-06-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Vaping"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03328936",
          "briefTitle": "Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2021-03-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Hematopoietic Cell Transplantation Recipient", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04588246",
          "briefTitle": "Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-08-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Breast Neoplasm", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Recurrent Brain Neoplasm", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04232241",
          "briefTitle": "Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-11-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-11-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia in Remission", "Acute Lymphoblastic Leukemia in Remission", "Myelodysplastic Syndromes"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 167,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05315570",
          "briefTitle": "Big Data for Quality of Life in Head and Neck Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-03-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Head and Neck Cancer", "Survivorship", "Quality of Life"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 420,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03787498",
          "briefTitle": "A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-03-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Relapsed Acute Myeloid Leukemia (AML)", "Refractory Acute Myeloid Leukemia (AML)", "High-risk Myelodysplastic Syndrome (MDS)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00824265",
          "briefTitle": "Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-03-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-10-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Leukaemia, Lymphocytic, Chronic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 365,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03524898",
          "briefTitle": "NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-10-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-02-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Soft Tissue Sarcoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01070134",
          "briefTitle": "Mindfulness-based Behavioural Therapy (MIBT) Versus Psychodynamic Therapy for Patients With Major Depressive Disorder in Psychotherapeutic Day Treatment. A Randomised Clinical Pilot Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-02"
          },
          "completionDateStruct": {
            "date": "2011-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Major Depressive Disorder", "Personality Disorder"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 84,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05908409",
          "briefTitle": "A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-06-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-03-22",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Multiple Myeloma (MM)", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Double Hit Lymphoma", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Chronic Lymphocytic Leukemia (CLL)", "Triple Hit Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05768932",
          "briefTitle": "BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-12-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-24",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Solid Tumor", "TNBC - Triple-Negative Breast Cancer", "Gastric Cancer", "Leukemia Acute Myeloid Leukemia (AML)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 260,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06381960",
          "briefTitle": "Clinical Study on the Prevention and Treatment of Postoperative Metastasis of Lung Cancer by Fuzheng Quxie Recipe"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-03-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 356,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06553274",
          "briefTitle": "Effect of Nutritional Intervention Based on Prediction Model on Adult Umbilical Cord Blood Transplantation Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-08",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Nutrition Disorders"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 67,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05841771",
          "briefTitle": "Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Hypomethylating Agent", "Venetoclax", "Myeloid Malignancy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 78,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07288034",
          "briefTitle": "Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-09-21",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-09-22",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 535,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03117751",
          "briefTitle": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-03-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Lymphoblastic Leukemia", "Acute Lymphoblastic Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 790,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "1 Year",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05080270",
          "briefTitle": "Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Multiple Sclerosis, Relapsing-Remitting", "Multiple Sclerosis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07251413",
          "briefTitle": "Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-10-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cutaneous Basal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07001384",
          "briefTitle": "A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-08-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2031-08-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Anaplastic Lymphoma Kinase", "Anaplastic Large Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06754540",
          "briefTitle": "Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-16",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia (AML)", "Relapse"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 51,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06421948",
          "briefTitle": "Linperlisib Combined With Chidamide in Patients With PTCL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-05-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Peripheral T-cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 134,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02839343",
          "briefTitle": "Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Adenocarcinoma", "Borderline Resectable Adenocarcinoma of the Head of the Pancrease"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 126,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05801913",
          "briefTitle": "Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["High Grade B-Cell Non-Hodgkin's Lymphoma", "Intermediate Grade B-Cell Non-Hodgkin's Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01817842",
          "briefTitle": "Study of Mobile Phone Support for the DC Tobacco Quitline"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-07"
          },
          "completionDateStruct": {
            "date": "2012-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Smoking Cessation"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 803,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06919666",
          "briefTitle": "NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2031-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04822532",
          "briefTitle": "Precision Dosing of Busulfan in Children Undergoing HSCT"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-06-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Hematopoietic Stem Cell Transplantation", "Allogeneic Hematopoietic Stem Cell Transplantation", "Autologous Hematopoietic Stem Cell Transplantation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 260,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05772559",
          "briefTitle": "Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-05-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2033-05-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Genetic Predisposition to Disease"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 500,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "25 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03801369",
          "briefTitle": "Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Triple-Negative Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01067846",
          "briefTitle": "Cognitive Enhancement and Relapse Prevention in Cocaine Addiction"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-06"
          },
          "completionDateStruct": {
            "date": "2012-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Cocaine Addiction"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 85,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05744375",
          "briefTitle": "Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-07-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Locally Advanced Breast Cancer", "Metastatic Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06217094",
          "briefTitle": "Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-02",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2030-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07111273",
          "briefTitle": "DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-08-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ulcerative Colitis (UC)", "Fecal Calprotetin", "FIT", "Biomarker"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02083250",
          "briefTitle": "Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-03-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-11-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia in Remission", "Allogeneic Hematopoietic Stem Cell Transplantation Recipient", "Myelodysplastic Syndrome", "Previously Treated Myelodysplastic Syndrome", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 70,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03598218",
          "briefTitle": "Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-07-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-04-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Nasopharyngeal Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06037018",
          "briefTitle": "Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-08-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-hodgkin Lymphoma", "Acute Lymphoblastic Leukaemia", "Chronic Lymphocytic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 44,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05042934",
          "briefTitle": "Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-09-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2022-08-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Ewing Sarcoma", "Recurrent Ewing Sarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "16 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04356209",
          "briefTitle": "Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic \" Patient Reported Outcome \") on Breast-related Quality of Life"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-01-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2031-01-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 105,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02876081",
          "briefTitle": "Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "SMALL CELL LUNG CARCINOMA"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00012298",
          "briefTitle": "Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2001-04"
          },
          "completionDateStruct": {
            "date": "2010-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma", "Waldenstrm Macroglobulinemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 81,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06515678",
          "briefTitle": "Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-05-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-08-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "Antiangiogenic-Associated Hypertension", "Adjuvant Bevacizumab", "Hypertension"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 9464,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00792948",
          "briefTitle": "Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Lymphoblastic Leukemia", "Adult B Acute Lymphoblastic Leukemia", "Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Adult L1 Acute Lymphoblastic Leukemia", "Adult L2 Acute Lymphoblastic Leukemia", "Adult T Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 97,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02201108",
          "briefTitle": "Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-07-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-07-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 166,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "10 Years",
          "maximumAge": "17 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05099068",
          "briefTitle": "Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-11-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-09-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced / Metastic Solid Tumors", "Glioblastoma", "Chronic Leukemia Lymphocytic"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 500,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07153497",
          "briefTitle": "Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-05-27",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2030-04-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 132,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07057596",
          "briefTitle": "Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Mestastatic Uveal Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02243579",
          "briefTitle": "Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-10-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-04-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Mycosis Fungoides and Sezary Syndrome", "Refractory Mycosis Fungoides and Sezary Syndrome", "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7", "Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06659705",
          "briefTitle": "Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-08-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Ductal Adenocarcinoma (PDAC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01611766",
          "briefTitle": "Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-07-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Epithelial Cancer Recurrent", "Fallopian Tube Carcinoma", "Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 356,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03419741",
          "briefTitle": "Brain Stimulation For Cancer Smokers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-10-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Cancer of Head and Neck", "Breast Cancer", "Prostate Cancer", "Nicotine Dependence"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 11,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02082977",
          "briefTitle": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-04-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-06-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Cancer", "Neoplasms"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04660539",
          "briefTitle": "A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-05-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Neuromyelitis Optica Spectrum Disorder"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 119,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04708054",
          "briefTitle": "Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 324,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02180867",
          "briefTitle": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-07-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-23",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Alveolar Soft Part Sarcoma", "Angiomatoid Fibrous Histiocytoma", "Atypical Fibroxanthoma", "Clear Cell Sarcoma of Soft Tissue", "Epithelioid Malignant Peripheral Nerve Sheath Tumor", "Epithelioid Sarcoma", "Extraskeletal Myxoid Chondrosarcoma", "Extraskeletal Osteosarcoma", "Fibrohistiocytic Neoplasm", "Fibrosarcoma", "Inflammatory Myofibroblastic Tumor", "Intimal Sarcoma", "Leiomyosarcoma", "Liposarcoma", "Liver Embryonal Sarcoma", "Low Grade Fibromyxoid Sarcoma", "Low Grade Myofibroblastic Sarcoma", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Skin Granular Cell Tumor", "Malignant Triton Tumor", "Mesenchymal Chondrosarcoma", "Myxofibrosarcoma", "Myxoid Chondrosarcoma", "Myxoinflammatory Fibroblastic Sarcoma", "Nerve Sheath Neoplasm", "PEComa", "Pericytic Neoplasm", "Plexiform Fibrohistiocytic Tumor", "Sclerosing Epithelioid Fibrosarcoma", "Skin Glomus Tumor", "Stage IB Soft Tissue Sarcoma AJCC v7", "Stage IIB Soft Tissue Sarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Synovial Sarcoma", "Undifferentiated High Grade Pleomorphic Sarcoma of Bone"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 140,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "2 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07003295",
          "briefTitle": "Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-08-14",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-08-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06858501",
          "briefTitle": "Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-03-22",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-12-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ganglioneuroblastoma", "Ganglioneuroblastoma, Nodular", "High Risk Neuroblastoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 84,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07225985",
          "briefTitle": "Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-05-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2030-11-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent T-Cell Non-Hodgkin Lymphoma", "Refractory T-Cell Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01064401",
          "briefTitle": "Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon  1a in Participants With Relapsing-Remitting Multiple Sclerosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-05"
          },
          "completionDateStruct": {
            "date": "2014-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsing-Remitting Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1841,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02255656",
          "briefTitle": "Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-01-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-07-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsing Remitting Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1062,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ],
    "protocolSection.2": [
      {
        "identificationModule": {
          "nctId": "NCT05010772",
          "briefTitle": "Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 125,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06709495",
          "briefTitle": "Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Sarcoma", "Sarcoma, Ewing", "Desmoplastic Small Round Cell Tumor", "Refractory Sarcoma", "Osteosarcoma", "Rhabdomyosarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 63,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years",
          "maximumAge": "49 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01682031",
          "briefTitle": "Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-06"
          },
          "completionDateStruct": {
            "date": "2012-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Chemotherapeutic Agent Toxicity", "Mucositis", "Radiation Toxicity", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Xerostomia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00315731",
          "briefTitle": "A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2003-03-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2013-06-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, Follicular"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03336931",
          "briefTitle": "PRecISion Medicine for Children With Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-09-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2032-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Childhood Cancer", "Childhood Solid Tumor", "Childhood Brain Tumor", "Childhood Leukemia", "Refractory Cancer", "Relapsed Cancer"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 550,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05674422",
          "briefTitle": "GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-05-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Patients With Locally Advanced Rectal Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06946602",
          "briefTitle": "Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-05-20",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-10-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["AML", "Elderly"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 307,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04044378",
          "briefTitle": "Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-08-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Effect of Drugs", "Progression", "Pediatric Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03800719",
          "briefTitle": "Personalized Support Using Instant Messaging Applications to Increase Smoking Cessation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Smoking Cessation"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 696,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03040206",
          "briefTitle": "Risk Stratification of Nodal PTCL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Angioimmunoblastic T-cell Lymphoma", "Anaplastic Large Cell Lymphoma, ALK-negative"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 405,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02888964",
          "briefTitle": "Pioglityazone and Imatinib for CML Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-12"
          },
          "completionDateStruct": {
            "date": "2016-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Leukemia, Myeloid, Chronic-Phase"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 27,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02674217",
          "briefTitle": "Outpatient Hematopoietic Grafting in Multiple Sclerosis Employing Autologous Peripheral Blood Stem Cells"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-05"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1000,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01258998",
          "briefTitle": "Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-12"
          },
          "completionDateStruct": {
            "date": "2015-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Chronic Lymphocytic Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Hairy Cell Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Waldenstrm Macroglobulinemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05987241",
          "briefTitle": "Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-09-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Muscle Invasive Bladder Urothelial Carcinoma", "Muscle Invasive Renal Pelvis Urothelial Carcinoma", "Muscle Invasive Ureter Urothelial Carcinoma", "Muscle Invasive Urethral Urothelial Carcinoma", "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage IV Bladder Urothelial Carcinoma AJCC v7"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 992,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06130332",
          "briefTitle": "Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-08-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Oral Cancer", "PD-1"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02863107",
          "briefTitle": "Young-Onset Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-06-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-08-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Colon Adenocarcinoma", "Colorectal Carcinoma", "Rectal Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 818,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05320380",
          "briefTitle": "A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-08-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2023-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Acute Myeloid Leukemia", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Recurrent T Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Mixed Phenotype Acute Leukemia", "Refractory T Acute Lymphoblastic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Months",
          "maximumAge": "22 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06717295",
          "briefTitle": "The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-08-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Brest Cancer", "Lung Cancer (NSCLC)", "Pancreatic Cancer, Adult", "Prostate Cancers", "Ovarian Cancer", "Colorectal Cancer", "Glioblastoma (GBM)", "Liver Carcinoma"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 6000,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "40 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02047734",
          "briefTitle": "Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-12-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-04-13",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsing Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1320,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00866281",
          "briefTitle": "A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-09"
          },
          "completionDateStruct": {
            "date": "2014-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "3 Months",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02007044",
          "briefTitle": "Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-12-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Prolymphocytic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 66,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04239989",
          "briefTitle": "Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-10-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Bronchiolitis Obliterans"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05328297",
          "briefTitle": "A Study of JNJ-55308942 in the Treatment of Bipolar Depression"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-05-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Bipolar Disorder"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 116,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "64 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04622761",
          "briefTitle": "Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-05-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03034473",
          "briefTitle": "Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC-II-IV, With a 5-Fluorouracil-based Standard Radiochemotherapy Followed by Total Mesorectal Excision."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-08"
          },
          "completionDateStruct": {
            "date": "2024-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Locally Advanced Rectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "85 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04677543",
          "briefTitle": "Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-05-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Mycobacterium Infections, Nontuberculous"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 99,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01222715",
          "briefTitle": "Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-10"
          },
          "completionDateStruct": {
            "date": "2015-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adult Rhabdomyosarcoma", "Childhood Alveolar Rhabdomyosarcoma", "Childhood Pleomorphic Rhabdomyosarcoma", "Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features", "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Childhood Rhabdomyosarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 87,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "29 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06179888",
          "briefTitle": "Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-08-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 78,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06822855",
          "briefTitle": "Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Classical Hodgkin Lymphoma", "Classical Hodgkin Lymphoma Recurrent", "Classical Hodgkin Lymphoma Refractory"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 755,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01185821",
          "briefTitle": "Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-08-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-10-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsing Remitting Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 185,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "56 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01612247",
          "briefTitle": "Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-02"
          },
          "completionDateStruct": {
            "date": "2014-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 13,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00899093",
          "briefTitle": "YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-09"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": ["Fallopian Tube Adenocarcinoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Malignant Ovarian Brenner Tumor", "Malignant Ovarian Clear Cell Tumor", "Malignant Ovarian Endometrioid Tumor", "Malignant Ovarian Mixed Epithelial Tumor", "Malignant Ovarian Mucinous Tumor", "Malignant Ovarian Neoplasm", "Malignant Ovarian Serous Tumor", "Malignant Ovarian Transitional Cell Tumor", "Ovarian Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Undifferentiated Fallopian Tube Carcinoma", "Undifferentiated Ovarian Carcinoma"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 2500,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00530348",
          "briefTitle": "Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study One"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-08"
          },
          "completionDateStruct": {
            "date": "2011-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Sclerosis, Relapsing-Remitting"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 581,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "50 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06948084",
          "briefTitle": "Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-29",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-02-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Multiple Myeloma", "Refractory Multiple Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06124989",
          "briefTitle": "Machine learnINg for the rElapse Risk eValuation in Acute Biliary Pancreatitis."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Pancreatitis", "Pancreatitis Due to Gallstones", "Pancreatitis Biliary", "Pancreatitis Relapsing"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 430,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05597085",
          "briefTitle": "A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-03-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-07-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 32,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06911710",
          "briefTitle": "The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-02-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)", "AML (Acute Myelogenous Leukemia)", "Myeloma Multiple", "B-ALL", "T-ALL/Lymphoma", "T-lymphocyte Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03141203",
          "briefTitle": "Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-07-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-09-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Peripheral T Cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "16 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03598270",
          "briefTitle": "Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-11-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-08-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Ovarian Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 417,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06504459",
          "briefTitle": "Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-05-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Monocytic Leukemia", "Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07226115",
          "briefTitle": "Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-18",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Colorectal Cancer", "Colorectal Cancer Recurrent", "Colorectal Cancer Stage II", "Colorectal Cancer Stage III"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01377870",
          "briefTitle": "Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-12"
          },
          "completionDateStruct": {
            "date": "2014-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03870750",
          "briefTitle": "Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-08-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Hematopoietic and Lymphoid Cell Neoplasm", "Non-Neoplastic Hematologic and Lymphocytic Disorder"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 458,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03959241",
          "briefTitle": "TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-06-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-09-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Leukemia", "Chronic Myelogenous Leukemia (CML)", "Myelodysplasia", "Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 431,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03856112",
          "briefTitle": "Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-06-21",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2021-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma", "t(11;14) Negative"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05201612",
          "briefTitle": "Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC)."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-07-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02763384",
          "briefTitle": "BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-12-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-05-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["T-Acute Lymphoblastic Leukemia", "Adult T Lymphoblastic Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 12,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01112293",
          "briefTitle": "Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-04"
          },
          "completionDateStruct": {
            "date": "2014-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pleural Malignant Mesothelioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03491215",
          "briefTitle": "Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-02-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-02-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Graft Versus Host Disease"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "28 Days",
          "maximumAge": "17 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02861417",
          "briefTitle": "Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-08-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-08-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Hematopoietic and Lymphoid Cell Neoplasm", "High Risk Acute Myeloid Leukemia", "High Risk Myelodysplastic Syndrome", "Lymphoproliferative Disorder", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent High Risk Myelodysplastic Syndrome", "Recurrent Hodgkin Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 204,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03724604",
          "briefTitle": "NSE/Alb as a Prognostic Biomarker for Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small-Cell Lung"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 202,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04011085",
          "briefTitle": "Tw HER2 Positive Breast Cancer Productivity & Utility Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "HER2-positive Breast Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 300,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01950611",
          "briefTitle": "Proteasome Inhibition in Acute Promyelocytic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-05"
          },
          "completionDateStruct": {
            "date": "2018-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed Acute Promyelocytic Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "1 Year",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07295132",
          "briefTitle": "RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-11-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer Recurrent", "Platinum Sensitive Ovarian Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 160,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04128319",
          "briefTitle": "T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-11-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Steroid-Refractory Acute Graft Versus Host Disease"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00700401",
          "briefTitle": "POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin)."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-11"
          },
          "completionDateStruct": {
            "date": "2010-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatitis C, Chronic"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 262,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02332980",
          "briefTitle": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-02-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-01-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Nodal Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Splenic Marginal Zone Lymphoma", "Recurrent Waldenstrom Macroglobulinemia", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Refractory Follicular Lymphoma", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Nodal Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma", "Refractory Splenic Marginal Zone Lymphoma", "Refractory Waldenstrom Macroglobulinemia", "Richter Syndrome", "Waldenstrom Macroglobulinemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 65,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03497546",
          "briefTitle": "Exercise Following Bariatric Surgery for Severe/Morbid Obesity (EFIBAR)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-09-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Obesity, Morbid", "Bariatric Surgery Candidate"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03210662",
          "briefTitle": "Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-11-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent Aggressive Non-Hodgkin Lymphoma", "Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Aggressive Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory T-Cell Non-Hodgkin Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01371630",
          "briefTitle": "Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-08-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-25",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative", "Burkitt-Like Lymphoma With 11q Aberration", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Burkitt Lymphoma", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Burkitt Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 276,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06869356",
          "briefTitle": "Expanded Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer in China"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-01-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric Cancer Stage"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 1291,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06946654",
          "briefTitle": "Geriatric Assessment (GA) for Elderly Patients Undergoing Allo-HSCT"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-05-20",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-03-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Elderly", "Geriatric Assessment", "ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 176,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06094881",
          "briefTitle": "A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-12-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Immune Thrombocytopenia", "Treatment"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02997228",
          "briefTitle": "Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-01-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Metastatic Colorectal Adenocarcinoma", "Stage IV Colorectal Cancer AJCC v7"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00545233",
          "briefTitle": "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-01"
          },
          "completionDateStruct": {
            "date": "2010-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatitis C, Chronic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 155,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04641910",
          "briefTitle": "Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-06-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-06-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 201,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05564026",
          "briefTitle": "Molecular Epidemiology of Pediatric Germ Cell Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-04-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Germ Cell Tumor", "Germinoma", "Teratoma", "Embryonal Carcinoma", "Yolk Sac Tumor", "Choriocarcinoma", "Mixed Germ Cell Tumor", "Late Effects", "Pediatric Germ Cell Tumor"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 1151,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00134563",
          "briefTitle": "Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2004-09"
          },
          "completionDateStruct": {
            "date": "2010-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1088,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06349538",
          "briefTitle": "Identifying Markers of Disease Subtypes and Disease Progression in the Syndrome of Essential Tremor"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2034-04-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Essential Tremor"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06241092",
          "briefTitle": "AI-Based Multimodal Multi-tasks Analysis Reveals Tumor Molecular Heterogeneity, Predicts Preoperative Lymph Node Metastasis and Prognosis in Papillary Thyroid Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-01-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Papillary Thyroid Carcinoma; Molecular Heterogeneity; Multi-model Analysis; Artificial Intelligence; Lymph Node Metastases; Disease-free Survival"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 256,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01330173",
          "briefTitle": "Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-12"
          },
          "completionDateStruct": {
            "date": "2014-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00352027",
          "briefTitle": "Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-07-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-11-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hodgkin's Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 81,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02791217",
          "briefTitle": "Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-06"
          },
          "completionDateStruct": {
            "date": "2019-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphoma, B-Cell", "Follicular Lymphoma", "Hodgkin Lymphoma", "Multiple Myeloma"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "85 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06569680",
          "briefTitle": "Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Extranodal Marginal Zone Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06515106",
          "briefTitle": "Antibody-mediated LGI1 Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Chronic Phase of the Disease"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-12-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Limbic Encephalitis With LGI1 Antibodies"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06290739",
          "briefTitle": "A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-11-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Intrahepatic Cholangiocarcinoma", "Machine Learning"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 483,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03536039",
          "briefTitle": "RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-01-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-01-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, Large B-Cell, Diffuse"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 28,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02101853",
          "briefTitle": "Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-12-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-09-16",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent B Acute Lymphoblastic Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 669,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "1 Year",
          "maximumAge": "31 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03038672",
          "briefTitle": "Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10-24",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["ALK-Positive Large B-Cell Lymphoma", "Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Mucocutaneous Ulcer", "HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Intravascular Large B-Cell Lymphoma", "Large B-Cell Lymphoma With 11q Aberration", "Large B-Cell Lymphoma With IRF4 Rearrangement", "Plasmablastic Lymphoma", "Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System", "Primary Effusion Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Gray-Zone Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent Lymphomatoid Granulomatosis", "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Burkitt Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Gray-Zone Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00923130",
          "briefTitle": "Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-01-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02268045",
          "briefTitle": "Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-05"
          },
          "completionDateStruct": {
            "date": "2017-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Diffuse Large B-cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 272,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06317662",
          "briefTitle": "Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Leukemia of Ambiguous Lineage", "B Acute Lymphoblastic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 153,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "365 Days"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07270861",
          "briefTitle": "Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-11-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2035-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Peripheral T-Cell Lymphoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 3000,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02927262",
          "briefTitle": "A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-02-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia (AML)", "Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 98,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03574077",
          "briefTitle": "Semi-personalized IM Smoking Cessation Interventions"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-12-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-10-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Smoking Cessation"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 119,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03269669",
          "briefTitle": "Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-01-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma", "Recurrent Follicular Lymphoma", "Refractory Follicular Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 95,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02906696",
          "briefTitle": "Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-10-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-08-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Blasts Under 15 Percent of Bone Marrow Nucleated Cells", "Blasts Under 15 Percent of Peripheral Blood White Cells", "Blasts Under 30 Percent of Bone Marrow Nucleated Cells", "Blasts Under 30 Percent of Peripheral Blood White Cells", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02048813",
          "briefTitle": "Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-03-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Anemia", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 529,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02114502",
          "briefTitle": "Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-09"
          },
          "completionDateStruct": {}
        },
        "conditionsModule": {
          "conditions": "Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01913951",
          "briefTitle": "Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-11-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-04-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Myelodysplastic Syndromes"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06203912",
          "briefTitle": "Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Multiple Myeloma", "Refractory Multiple Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 3,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03787056",
          "briefTitle": "Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-01-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cancer", "Prostate Cancer", "Melanoma", "Lung Cancer", "Hepatocellular Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Glioblastoma", "Endometrial Cancer", "Bladder Cancer", "Esophageal Cancer", "B-cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 410,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06281847",
          "briefTitle": "An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2041-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia, in Relapse", "Acute Myeloid Leukemia Refractory"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 143,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06064097",
          "briefTitle": "A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage II Nasopharyngeal Carcinoma AJCC v8", "Stage III Nasopharyngeal Carcinoma AJCC v8", "Stage IV Nasopharyngeal Carcinoma AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03907488",
          "briefTitle": "Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-08-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-03-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma", "Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma", "Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma", "Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma", "Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma", "Classic Hodgkin Lymphoma", "Lymphocyte-Rich Classic Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 994,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02654990",
          "briefTitle": "Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-04-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-08-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 248,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01814488",
          "briefTitle": "A Phase II Study on Allogeneic Stem Cell Transplantation in Patients With Active Acute Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-07"
          },
          "completionDateStruct": {
            "date": "2017-06-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 101,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06141473",
          "briefTitle": "Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-12-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-05-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Sclerosis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1600,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05913141",
          "briefTitle": "PDO/PDO-TIL/PDOTS for Drug Screen"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-06",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Liver Cancer", "Metastatic Liver Cancer"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "90 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06720701",
          "briefTitle": "Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Hodgkin Lymphoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 125,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ]
  }
}
